Text Size

Pharmacokinetic (PK) Study in Japanese Non-epileptic Renal Impaired Patients

This study has been completed.
Sponsor:
Collaborator:
Parexel
Information provided by (Responsible Party):
UCB, Inc.
ClinicalTrials.gov Identifier:
NCT01491113
First received: December 9, 2011
Last updated: November 27, 2012
Last verified: November 2012
History of Changes
  Purpose

This is a human pharmacology, single-dose study to investigate the pharmacokinetics of orally administered Levetiracetam (LEV) in Japanese subjects with normal renal function and in Japanese subjects with various degrees of impaired renal function.


Condition Intervention Phase
Healthy Subjects
Renal Impairments
 Drug: Levetiracetam 250 mg
Drug: Levetiracetam 500 mg
 Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Basic Science
Official Title: Single-Dose Pharmacokinetics of Orally Administered Levetiracetam (LEV) in Japanese Subjects With Normal Renal Function and Various Degrees of Renal Impairment Using a Dosing Regimen Adjusted to Renal Function (250 mg or 500 mg)

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by UCB, Inc.:

Primary Outcome Measures:
  • Maximum observed blood concentration (Cmax) of ucb L059 (LEV) for groups A to D [ Time Frame: From Baseline up to 144 hours post first dose ] [ Designated as safety issue: No ]
    Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours

  • Area under the concentration-time curve (AUC(0-t)) of ucb L059 (LEV) from Baseline to the last quantifiable concentration for groups A to D [ Time Frame: From Baseline up to 144 hours post first dose ] [ Designated as safety issue: No ]
    Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours

  • Maximum observed blood concentration (Cmax) of ucb L057 for groups A to D [ Time Frame: From Baseline up to 144 hours post first dose ] [ Designated as safety issue: No ]
    Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours

  • Area under the concentration-time curve (AUC(0-t)) of ucb L057 from Baseline to the last quantifiable concentration for groups A to D [ Time Frame: From Baseline up to 144 hours post first dose ] [ Designated as safety issue: No ]
    Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours

  • Maximum observed blood concentration (Cmax) of ucb L059 (LEV) for group E during first period [ Time Frame: From Baseline to 44 hours post first dose ] [ Designated as safety issue: No ]
  • Area under the concentration-time curve (AUC(0-t)) of ucb L059 (LEV) from Baseline to 44 hours for group E [ Time Frame: From Baseline to 44 hours post first dose ] [ Designated as safety issue: No ]
  • Maximum observed blood concentration (Cmax) of ucb L057 for group E during first period [ Time Frame: From Baseline to 44 hours post first dose ] [ Designated as safety issue: No ]
  • Area under the concentration-time curve (AUC(0-t)) of ucb L057 from Baseline to 44 hours for group E [ Time Frame: From Baseline to 44 hours post first dose ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Total amount excreted in urine (Ae) of ucb L059 (LEV) for groups A to D [ Time Frame: From Baseline up to 144 hours post first dose ] [ Designated as safety issue: No ]
    Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours

  • Fraction of dose excreted in urine (fe) of ucb L059 (LEV) for groups A to D [ Time Frame: From Baseline up to 144 hours post first dose ] [ Designated as safety issue: No ]
    Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours

  • Renal Clearance (CLR) of ucb L059 (LEV) for groups A to D [ Time Frame: From Baseline up to 144 hours post first dose ] [ Designated as safety issue: No ]
    Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours

  • Apparent total body Clearance (CL/F) of ucb L059 (LEV) for groups A to D [ Time Frame: From Baseline up to 144 hours post first dose ] [ Designated as safety issue: No ]
    Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours

  • Nonrenal Clearance (CLNR) of ucb L059 (LEV) for groups A to D [ Time Frame: From Baseline up to 144 hours post first dose ] [ Designated as safety issue: No ]
    Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours

  • Total amount excreted in urine (Ae) of ucb L057 for groups A to D [ Time Frame: From Baseline up to 144 hours post first dose ] [ Designated as safety issue: No ]
    Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours

  • Renal Clearance (CLR) of ucb L057 for groups A to D [ Time Frame: From Baseline up to 144 hours post first dose ] [ Designated as safety issue: No ]
    Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours

  • Apparent total body Clearance (CL/F) of ucb L059 (LEV) for group E during first period [ Time Frame: From Baseline to 44 hours post first dose ] [ Designated as safety issue: No ]
  • Time to reach maximum blood concentration (tmax) of ucb L059 (LEV) for groups A to D [ Time Frame: From Baseline up to 144 hours post first dose ] [ Designated as safety issue: No ]
    Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours

  • Area under the concentration-time curve (AUC) of ucb L059 (LEV) from Baseline to infinite for groups A to D [ Time Frame: From Baseline up to 144 hours post first dose ] [ Designated as safety issue: No ]
    Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours

  • Terminal half-life (t1/2) of ucb L059 (LEV) for groups A to D [ Time Frame: From Baseline up to 144 hours post first dose ] [ Designated as safety issue: No ]
    Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours

  • Time to reach maximum blood concentration (tmax) of ucb L057 for groups A to D [ Time Frame: From Baseline up to 144 hours post first dose ] [ Designated as safety issue: No ]
    Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours

  • Area under the concentration-time curve (AUC) of ucb L057 from Baseline to infinite for groups A to D [ Time Frame: From Baseline up to 144 hours post first dose ] [ Designated as safety issue: No ]
    Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours

  • Terminal half-life (t1/2) of ucb L057 for groups A to D [ Time Frame: From Baseline up to 144 hours post first dose ] [ Designated as safety issue: No ]
    Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours

  • Time to reach maximum blood concentration (tmax) of ucb L059 (LEV) for group E during first period [ Time Frame: From Baseline to 44 hours post first dose ] [ Designated as safety issue: No ]
  • Area under the concentration-time curve (AUC) of ucb L059 (LEV) from Baseline to infinite for group E [ Time Frame: From Baseline to 140 hours post first dose ] [ Designated as safety issue: No ]
  • Terminal half-life (t1/2) of ucb L059 (LEV) for group E during first period [ Time Frame: From Baseline to 44 hours post first dose ] [ Designated as safety issue: No ]
  • Time to reach maximum blood concentration (tmax) of ucb L057 for group E during first period [ Time Frame: From Baseline to 44 hours post first dose ] [ Designated as safety issue: No ]
  • Hemodialysis clearance (CLD) of ucb L059 (LEV) during first dialysis for group E [ Time Frame: From 44 hours to 48 hours post first dose ] [ Designated as safety issue: No ]
    Calculated by the Arterio - Venous difference method and cumulative dialysate method.

  • Ultrafiltration clearance (CLUF) of ucb L059 (LEV) during first dialysis for group E [ Time Frame: From 44 hours to 48 hours post first dose ] [ Designated as safety issue: No ]
    Calculated by the Arterio - Venous difference method and cumulative dialysate method.

  • Hemodialysis clearance (CLHD) of ucb L059 (LEV) during first dialysis for group E [ Time Frame: From 44 hours to 48 hours post first dose ] [ Designated as safety issue: No ]
    Calculated according: CLHD=CLD+CLUF.


Enrollment: 32
Study Start Date: November 2011
Study Completion Date: November 2012
Primary Completion Date: November 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Group A: Normal renal function

Subjects who have normal renal function (CLcr >80 mL/min/1.73 m^2). Subjects will be orally administered LEV 500 mg once. After LEV administration, safety assessments and blood and urine samplings will be taken through to Day 4 during the Treatment Period, and safety follow-up assessments will be performed on Day 8 according to the schedule of study assessments.

  • Blood samples for PK: Predose (Baseline), and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours postdose
  • Urine samples for PK: 0 - 6, 6 - 12, 12 - 24, 24 - 48, 48 - 72 hours postdose
 Drug: Levetiracetam 500 mg
Tablet containing Levetiracetam 500 mg
Other Name: E-Keppra
Experimental: Group B: Mild renal impairment

Patients who have mild renal impairment (50<CLcr <80 mL/min/1.73 m^2). Subjects will be orally administered LEV 500 mg once. After LEV administration, safety assessments and blood and urine samplings will be conducted through Day 5 during the Treatment Period, and safety follow-up assessments will be performed on Day 8 according to the schedule of study assessments.

  • Blood samples for PK: Predose (Baseline), and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96 hours postdose
  • Urine samples for PK: 0 - 6, 6 - 12, 12 - 24, 24 - 48, 48 - 72, 72 - 96 hours postdose
 Drug: Levetiracetam 500 mg
Tablet containing Levetiracetam 500 mg
Other Name: E-Keppra
Experimental: Group C: Moderate renal impairment

Patients who have moderate renal impairment (30<CLcr < 50 mL/min/1.73 m^2). Subjects will be orally administered LEV 250 mg once. After LEV administration, safety assessments and blood and urine samplings will be conducted through Day 6 during the Treatment Period, and safety follow-up assessments will be performed on Day 8 according to the schedule of study assessments.

  • Blood samples for PK: Predose (Baseline), and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours postdose
  • Urine samples for PK: 0 - 6, 6 - 12, 12 - 24, 24 - 48, 48 - 72, 72 - 96, 96 -120 hours postdose
 Drug: Levetiracetam 250 mg
Tablet containing Levetiracetam 250 mg
Other Name: E-Keppra
Experimental: Group D: Severe renal impairment

Patients who have severe renal impairment (CLcr <30 mL/min/1.73 m^2). Subjects will be orally administered LEV 250 mg once. After LEV administration, safety assessments and blood and urine samplings will be conducted through Day 7 during the Treatment Period, and safety follow-up assessments will be performed on Day 8 according to the schedule of study assessments.

  • Blood samples for PK: Predose (Baseline), and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144 hours postdose
  • Urine samples for PK: 0 - 6, 6 - 12, 12 - 24, 24 - 48, 48 - 72, 72 - 96, 96 -120, 120 - 144 hours postdose
 Drug: Levetiracetam 250 mg
Tablet containing Levetiracetam 250 mg
Other Name: E-Keppra
Experimental: Group E: End-stage renal disease

Group E will receive LEV 500 mg on Day 1, 44 h before the first hemodialysis. As a supplementary dose LEV 250 mg will be administered 1 h after the end of the first hemodialysis on Day 3.

The 4-hour Hemodialysis are scheduled as follows:

  1. Dialysis: 44 h to 48 h after the first dose (Day 3)
  2. Dialysis: 92 h to 96 h after the first dose (Day 5)
  3. Dialysis: 140 h after the first dose (Day 7)

Safety assessments and blood samplings will be conducted until Day 7. Safety follow-up assessments will be performed on Day 10.

Blood samples for PK: Predose (Baseline), and 0.5, 1, 2, 4, 6, 8, 12, 24, 30, 44*, 44.25*, 44.5*, 45*, 46*, 47*, 48*, 49, 49.5, 50, 51, 53, 55, 57, 61, 73, 92, 96, 120, 140 hours post first dosing.

49 h-sample should be taken before the additional dose. The 44 h, 92 h, and 140 h sample should be taken before the start of the hemodialysis.

*Inflow blood, outflow blood, and dialysate fluid will be collected.

 Drug: Levetiracetam 250 mg
Tablet containing Levetiracetam 250 mg
Other Name: E-Keppra
Drug: Levetiracetam 500 mg
Tablet containing Levetiracetam 500 mg
Other Name: E-Keppra

Detailed Description:

The primary objective of this study is to evaluate the plasma and urine PK of Levetiracetam (ucb L059) and its metabolite (ucb L057) after a single dose of LEV 250 mg or LEV 500 mg in Japanese subjects with normal renal function and in Japanese subjects with various degrees of renal impairment.

  Eligibility

Ages Eligible for Study:   20 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy subjects with normal renal function
  • Subject is Japanese
  • Subjects with creatinine clearance within 1 of 3 Groups (CLcr[mL/min/1.73 cm^2]: Group B: 50 - <80, Group C: 30 - <50, Group D: <30), or for Group E, subjects with end-stage renal failure undergoing hemodialysis

Exclusion Criteria:

  • Subjects has taken any drug treatment, disease or injury to influence Levetiracetam PK except for renal impairments
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01491113

Locations
Japan
1
Fukuoka, Japan
2
Ibaraki, Japan
Sponsors and Collaborators
UCB, Inc.
Parexel
Investigators
Study Director: UCB Clinical Trial Call Center +1 877 822 9493 (UCB)
  More Information

No publications provided

Responsible Party: UCB, Inc.
ClinicalTrials.gov Identifier: NCT01491113     History of Changes
Other Study ID Numbers: N01373
Study First Received: December 9, 2011
Last Updated: November 27, 2012
Health Authority: Japan: Ministry of Health, Labor and Welfare

Keywords provided by UCB, Inc.:
Levetiracetam
Oral administration
Japanese
 Non-epileptic
Healthy
Renal impaired subjects

Additional relevant MeSH terms:
Renal Insufficiency
Kidney Diseases
Urologic Diseases
Etiracetam
Piracetam
Anticonvulsants
Central Nervous System Agents
 Therapeutic Uses
Pharmacologic Actions
Nootropic Agents
Neuroprotective Agents
Protective Agents
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on May 21, 2013